All In Biotech

Drug Trial Radar · NCT07044297

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 4,390 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,390

Actual

Start

Jul 31, 2025

Primary completion

Jul 22, 2027

Study completion Jul 22, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it

Conditions

  • Human Immunodeficiency Virus (HIV)
  • HIV Pre-Exposure Prophylaxis

Interventions

  • MK-8527Drug

    Oral tablet

  • FTC/TDFDrug

    Oral tablet

  • Placebo to MK-8527Drug

    Placebo tablet matched to MK-8527

  • Placebo to FTC/TDFDrug

    Placebo tablet matched to FTC/TDF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) InfectionTime frame: Up to approximately 2 years
  2. Number of Participants Who Experience At Least One Adverse Event (AE)Time frame: Up to approximately 2 years
  3. Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 2 years

Locations

81 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0006)

    Birmingham, Alabama

  • USA Health University Hospitals ( Site 0020)

    Mobile, Alabama

  • UCLA Center for Clinical AIDS Research and Education ( Site 0004)

    Los Angeles, California

  • Bridge HIV - San Francisco Department of Public Health ( Site 0001)

    San Francisco, California

  • Whitman-Walker Institute ( Site 0016)

    Washington D.C., District of Columbia

  • University of Miami RAPID Research ( Site 0003)

    Miami, Florida

  • Orlando Immunology Center ( Site 0021)

    Orlando, Florida

  • Hope Clinic of the Emory Vaccine Center ( Site 0009)

    Decatur, Georgia

  • University of Illinois Chicago ( Site 0027)

    Chicago, Illinois

  • University Medical Center New Orleans ( Site 0024)

    New Orleans, Louisiana

  • Open Arms Healthcare Center ( Site 0025)

    Jackson, Mississippi

  • Rutgers New Jersey Medical School ( Site 0010)

    Newark, New Jersey

  • Montefiore Medical Center ( Site 0017)

    The Bronx, New York

  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill ( Site 0008)

    Chapel Hill, North Carolina

  • Regional Center for Infectious Diseases ( Site 0018)

    Greensboro, North Carolina

  • Philadelphia Fight Community Health Centers ( Site 0011)

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0022)

    Pittsburgh, Pennsylvania

  • Prisma Health Richland Hospital-Clinical Research Unit ( Site 0007)

    Columbia, South Carolina

  • St. Jude Children's Research Hospital ( Site 0026)

    Memphis, Tennessee

  • Meharry Medical College ( Site 0013)

    Nashville, Tennessee

  • Central Texas Clinical Research ( Site 0014)

    Austin, Texas

  • Saint Hope Foundation, Inc. ( Site 0015)

    Bellaire, Texas

  • Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0002)

    Seattle, Washington

  • Fundación IDEAA ( Site 0351)

    Buenos Aires, Argentina

  • Centro de Estudios Infectológicos S.A. ( Site 0357)

    CABA, Buenos Aires, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0352)

    CABA, Buenos Aires, Argentina

  • Fundación Huésped ( Site 0350)

    CABA, Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0353)

    Mar del Plata, Buenos Aires, Argentina

  • Instituto Nacional de Infectologia Evandro Chagas ( Site 0407)

    Rio de Janeiro, Brazil

  • Fundaçao de Medicina Tropical Doutor Heitor Vieira Dourado ( Site 0412)

    Manaus, Amazonas, Brazil

  • Obras Sociais Irma Dulce ( Site 0406)

    Salvador, Estado de Bahia, Brazil

  • School of Medicine Federal University of Minas Gerais ( Site 0417)

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital Geral de Nova Iguacu ( Site 0411)

    Nova Iguaçu, Rio de Janeiro, Brazil

  • Ricardo Diaz Scientific Solutions ( Site 0402)

    São Paulo, São Paulo, Brazil

  • Centro de Referência e Treinamento DST/AIDS ( Site 0400)

    São Paulo, São Paulo, Brazil

  • Hospital das Clinicas FMUSP ( Site 0401)

    São Paulo, São Paulo, Brazil

  • Hospital Dr. Hernán Henríquez Aravena ( Site 0451)

    Temuco, Araucania, Chile

  • Universidad San Sebastian - Providencia ( Site 0454)

    Santiago, Region M. de Santiago, Chile

  • Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 0450)

    Santiago, Region M. de Santiago, Chile

  • IPS SURA San Diego ( Site 0500)

    Medellín, Antioquia, Colombia

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.